Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 19/20 | 0.52 |
| ▸ | PRKAA1 | Q13131 | 19/20 | 0.52 |
| ▸ | PRKAB1 | Q9Y478 | 19/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 18/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 18/20 | 0.52 |
| ▸ | PRKAG3 | Q9UGI9 | 18/20 | 0.52 |
| ▸ | PRKAG2 | Q9UGJ0 | 18/20 | 0.52 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22915231 | 0.88 | EIF4A3 (0.51) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL12393388 | 0.83 | PRKAG1 (0.46) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL30443279 | 0.76 | MAP2K4 (0.61) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL7379535 | 0.76 | MAP2K4 (0.61) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL12090187 | 0.76 | MAPK1 (0.50) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL6598584 | 0.76 | PRKAG1 (0.55) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL27757354 | 0.75 | PRKAG1 (0.43) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL176936 | 0.74 | PRKAG1 (0.55) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL12879075 | 0.74 | PRKAG1 (0.46) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL261067 | 0.73 | IDO1 (0.62) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043057-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070015771-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015771-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | PRKAG1 2241/4885PRKAA1 3682/4885PRKAB1 2963/4885 |
| US-20070043057-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | PRKAG1 2241/4885PRKAA1 3682/4885PRKAB1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.